Treatment of type 2 diabetes mellitus worldwide Baseline patient characteristics in the global DISCOVER study.pdf (500.53 kB)
Download file

Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.

Download (500.53 kB)
journal contribution
posted on 24.06.2019, 10:31 by MB Gomes, W Rathmann, B Charbonnel, K Khunti, M Kosiborod, A Nicolucci, SJ Pocock, MV Shestakova, I Shimomura, F Tang, H Watada, H Chen, J Cid-Ruzafa, P Fenici, N Hammar, F Surmont, L Ji, DISCOVER investigators
AIMS: To describe the characteristics and treatment of patients with type 2 diabetes mellitus initiating a second-line glucose-lowering therapy in the global DISCOVER study programme. METHODS: DISCOVER comprises two similar 3-year prospective observational studies (NCT02322762 and NCT02226822), involving 15,992 patients initiating a second-line glucose-lowering therapy in 38 countries across six regions (Africa, Americas, South-East Asia, Eastern Mediterranean, Europe and Western Pacific). RESULTS: Overall, 54.2% of patients were male (across region range [ARR]: 37.7-58.6%). At baseline, mean age and time since diagnosis of type 2 diabetes mellitus were 57.2 (ARR: 53.1-61.9)and 5.6 (ARR: 4.6-6.9) years, respectively. Median glycated haemoglobin (HbA1c) was 63.9 mmol/mol (8.0%; ARR: 7.6-8.3%). Microvascular and macrovascular complications were reported in 18.9% (ARR: 14.5-23.5%) and 12.7% (ARR: 5.0-26.6%) of patients, respectively. First-line treatments were mostly metformin monotherapy (55.6%; ARR: 42.5-83.6%) and combinations of metformin with a sulfonylurea (14.4%; ARR: 5.8-31.1%). The most commonly prescribed second-line therapies were combinations of metformin with a dipeptidyl peptidase-4 inhibitor (23.5%; ARR: 2.2-29.6%) or a sulfonylurea (20.9%; ARR: 13.6-57.1%). CONCLUSIONS: DISCOVER demonstrates considerable global variation in the treatment of type 2 diabetes mellitus, and a need for more aggressive risk factor control.


The authors would like to thank all investigators and patients participating in the DISCOVER study. Medical writing support was provided by Ste´phane Pintat PhD of Oxford PharmaGenesis, Oxford, UK, and was funded by AstraZeneca.



Diabetes Research and Clinical Practice, 2019, 151, pp. 20-32

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Diabetes Research Centre


VoR (Version of Record)

Published in

Diabetes Research and Clinical Practice


Elsevier for International Diabetes Federation



Acceptance date


Copyright date


Available date


Publisher version


Supplementary data to this article can be found online at



Usage metrics